Roche acquires Trophos to expand portfolio in neuromuscular disease with high medical need
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has agreed to acquire Trophos, a privately held biotechnology company based in Marseille, France. Trophos's proprietary screening platform generated olesoxime (TRO19622), which is being developed for SMA - a rare and debilitating genetic neuromuscular disease that is most commonly diagnosed in children.
Novartis Pharmaceuticals announces a joint investment company with Qualcomm
- Details
- Category: Novartis
Novartis Pharmaceuticals has announced the establishment of a joint investment company with Qualcomm Ventures to target early stage companies who offer technologies, products or services that "go beyond the pill" to benefit physicians and patients.
Roche enters a broad strategic collaboration with Foundation Medicine in the field of molecular information in oncology
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) and Foundation Medicine, Inc. (NASDAQ: FMI) announced today that they will enter into a broad strategic collaboration to further advance FMI's market-leading position in molecular information and genomic analysis while providing Roche a unique opportunity to optimize the identification and development of novel treatment options for cancer patients.
MedImmune enters licensing agreement with Omnis Pharmaceuticals for oncolytic viruses in immuno-oncology
- Details
- Category: AstraZeneca
AstraZeneca today announced that MedImmune, its global biologics research and development arm, has entered into a licensing agreement with Omnis Pharmaceuticals (Omnis), a privately-held biotechnology company focused on the development of oncolytic viruses.
Acquisition provides Pfizer with a preclinical CMV vaccine candidate
- Details
- Category: Pfizer
Pfizer Inc. has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a privately held Swiss biopharmaceutical company, based in Zurich-Schlieren. This transaction provides access to a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.
Novartis collaborates with Intellia Therapeutics and Caribou Biosciences
- Details
- Category: Novartis
Novartis announced today that it has signed collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology and Caribou Biosciences for the development of drug discovery tools. Intellia and Caribou are two of the leading biotechnology companies developing this novel technology.
Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) sign worldwide research collaboration
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE:BMY) and the California Institute for Biomedical Research (Calibr) announced today they have entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows Bristol-Myers Squibb to develop, manufacture and commercialize Calibr's preclinical compounds resulting from the collaboration.
More Pharma News ...
- New European consortium formed to help further advance development of a GSK/NIH Ebola candidate vaccine
- Abbott completes acquisition of Veropharm
- Pfizer expands rare disease research with establishment of gene therapy platform
- Jury verdict favours AstraZeneca in Nexium antitrust litigation
- Bristol-Myers Squibb Foundation awards nine grants to support care for high-risk patients with hepatitis B and C in China and India
- Amgen and AstraZeneca announce positive results from third and final pivotal Phase III study of Brodalumab in patients with moderate-to-severe plaque psoriasis
- GSK statement on first phase 1 trial results of a candidate Ebola vaccine